D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: A double-blind, parallel, placebo-controlled study

Neuropsychopharmacology

Volumn 21, Issue 2, 1999, Pages 203-210

  Van Berckel, B N M ^a   Evenblij, C N ^a   Van Loon, B J A M ^a   Maas, M F ^a   Van Der Geld, M A M ^d   Wynne, H J ^c   Van Ree, J M ^b   Kahn, R S ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d Utrecht and Psychiat Hosp veldwyk   (Netherlands)

Author keywords

D cycloserine; Glutamate; Glycine; Luteinizing hormone; Schizophrenia

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CYCLOSERINE; EXCITATORY AMINO ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; PLACEBO;

ADULT; ARTICLE; BEHAVIOR; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; LUTEINIZING HORMONE RELEASE; MALE; NEGATIVE SYNDROME; NEUROTRANSMISSION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA; SYMPTOM;

ADULT; ANTIMETABOLITES; ANTIPSYCHOTIC AGENTS; CYCLOSERINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLYCINE; HUMANS; LUTEINIZING HORMONE; MALE; MIDDLE AGED; PLACEBOS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0032974130     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00014-7     Document Type: Article

References (40)

1. Andreasen N.C. Comprehensive Assessment of Symptoms and History (CASH). 1985;University of Iowa, Iowa City.
2. Banerjee S.P., Zuck L.G., Yablonsky Alter E., Lidsky T.I. Glutamate agonist activity. Implications for antipsychotic drug action and schizophrenia Neuroreport. 6:1995;2500-2504.
3. Cascella N.G., Macciardi F., Cavallini C., Smeraldi E. D-Cycloserine adjuvant therapy to conventional neuroleptic treatment in zchizophreania. An open-label study J Neural Transm-Gen Sect. 95:1994;105-111.
4. Chessell I.P., Procter A.W., Francis P.T., Bowen D.M. D-cycloserine, a putative cognitive enhancer, facilitates activation of the N-methyl-D-aspartate receptor-ionophore complex in Alzheimer brain. Brain Res. 565:1991;345-348.
5. Chouinard G., Ross-Chouinard A., Annable L., Jones B.D. Extrapyramidal Symptom Rating Scale. Can Neurol Sci. 7:1980;3,233.
6. Emmett M.R., Mick S.J., Cler J.A., Rao T.S., Iyengar S., Wood P.L. Actions of D-cycloserine at the N-methyl-D-aspartate-associated glycine receptor site in vivo. Neuropharmacology. 30:1991;1167-1171.
7. Fletcher E.J., MacDonald J.F. Haloperidol interacts with the strychnine-insensitive glycine site at the NMDA receptor in cultured mouse hippocampal neurones. Eur J Pharmacol. 235:1993;291-295.
8. Gao X.M., Chen L.W., Tamminga C.A. Blockade of phencyclidine- and MK-801 induced regional zif268 mRNA expression. Schizophrenia Research. 24:1997;76.
9. Goff D.C., Tsai G.C., Manoach D.S., Coyle J.T. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry. 152:1995;1213-1215.
10. Goff D.C., Tsai G.C., Manoach D.S., Flood J., Darby D.G., Coyle J.T. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry. 153:1996;1628-1630.
11. Henn F.A. The NMDA receptor as a site for psychopathology-primary or secondary role? Arch Gen Psychiatry. 52:1995;1008-1010.
12. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Horowitz A., Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry. 169:1996;610-617.
13. Hood W.F., Compton R.P., Monahan J.B. D-cycloserine. A ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics Neurosci Lett. 98:1980;91-95.
14. Ishimaru M., Kurumaji A., Toru M. Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics. Evidence for glutamate hypothesis Biol Psychiatry. 35:1994;84-95.
15. Javitt D.C., Zylberman I., Zukin S.R., Heresco-Levy U., Lindenmayer J. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry. 151:1994;1234-1236.
16. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 148:1991;1301-1308.
17. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 13:1987;261-276.
18. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B. Jr., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses Arch Gen Psychiatry. 51:1994;199-214.
19. Lahti A.C., Koffel B., Laporte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 13:1995;9-19.
20. Lidsky T.I., Yablonskyalter E., Zuck L.G., Banerjee S.P. Antipsychotic drug effects on glutamatergic activity. Brain Res. 764:1997;46-52.
21. Luby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., Kelly R. Study of a new schizophrenomimetic drug-Sernyl. AMA Arch Neurol Psychiat. 81:1959;363-369.
22. Luby E.D., Gottlieb J.S., Cohen B.D., Rosenbaum G., Domino E.F. Model psychoses and schizophrenia. Am J Psychiatry. 199:1962;61-67.
23. Malhotra A.K., Adler C.M., Kennison S.D., Elman I., Pickar D., Breier A. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis. A study with ketamine Biol Psychiatry. 42:1997;664-668. a.
24. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pickar D., Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology. 17:1997;141-150. b.
25. McCoy L., Richfield E.K. Chronic antipsychotic treatment alters glycine-stimulated NMDA receptor binding in rat brain. Neurosci Lett. 213:1996;137-141.
26. Monahan J.B., Handelmann G.E., Wood W.F., Cordi A.A. D-cycloserine, a positive modulator of the N-methyl-D-aspartate receptor, enhances performance of learning tasks in rats. Pharmacol Biochem Behav. 34:1989;649-653.
27. 3H]kainic acid binding in the prefrontal cortex in schizophrenia. Neurosci Lett. 40:1983;245-250.
28. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psych. 52:1995;998-1007.
29. Paschen W. Glutamate excitotoxicity in transient global cerebral ischemia. Acta Neurobiol Exp. 56:1996;313-322.
30. Priestley T., Laughton P., Myers J., Le Bourdelles B., Kerby J., Whiting P.J. Pharmacological properties of recombinant human N-methyl-D-aspartate receptors comprising NR1a/NR2A and NR1a/NR2B subunit assemblies expressed in permanently transfected mouse fibroblast cells. Mol Pharmacol. 48:1995;841-848.
31. Quartermain D., Mower J., Rafferty M.F., Herting R.L., Lanthorn T.H. Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharmacol. 257:1994;7-12.
32. Rosse R.B., Faymccarthy M., Kendrick K., Davis R.E., Deutsch S.I. D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia. Clin Neuropharmacol. 19:1996;444-450.
33. Simeon J., Fink M., Itil T.M., Ponce D. d-Cycloserine therapy of psychosis by symptom provocation. Comp Psychiatry. 11:1970;80-88.
34. Toru M., Watanabe S., Shibuya H., Nishikawa T., Noda K., Mitsushio H., Ickikawa H., Kurumaji A., Takashima M., Mataga N., Ogawa A. Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta Psychiatr Scand. 78:1988;121-137.
35. Tsai G., Passani L.A., Slusher B.S., Carter R., Baer L., Leinman J.E., Coyle J.T. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry. 52:1995;829-836.
36. Van Berckel B.N.M., Hijman R., van der Linden J.A., Westenberg H.G.M., van Ree J.M., Kahn R.S. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biol Psychiatry. 40:1996;1298-1300.
37. Van Berckel B.N.M., Lipsch C., Timp S., Gispen de Wied C., Wynne H., van Ree J.M., Kahn R.S. Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects. Neuropsychopharmacology. 16:1997;317-324.
38. Van Berckel B.N.M., Oranje B., van Ree J.M., Verbaten M.N., Kahn R.S. The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects. Psychopharmacology. 137:1998;271-281. a.
39. Van Berckel B.N.M., Lipsch C., Gispen de Wied C.C., Wynne H.J., Blankenstein P.A., Vanree J.M., Kahn R.S. The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers. Psychopharmacology. 138:1998;190-197. b.
40. Walker W.C., Murdoch J.M. Cycloserine in the Treatment of Pulmonary Tuberculosis. A Report on Toxicity. Tubercle, Lond. 38:1957;297.